ATE469883T1 - 2-methylen-19-nor-1alpha-hydroxy-17- enhormopregnacalziferol und anwendungen davon - Google Patents
2-methylen-19-nor-1alpha-hydroxy-17- enhormopregnacalziferol und anwendungen davonInfo
- Publication number
- ATE469883T1 ATE469883T1 AT05851805T AT05851805T ATE469883T1 AT E469883 T1 ATE469883 T1 AT E469883T1 AT 05851805 T AT05851805 T AT 05851805T AT 05851805 T AT05851805 T AT 05851805T AT E469883 T1 ATE469883 T1 AT E469883T1
- Authority
- AT
- Austria
- Prior art keywords
- skin
- compound
- methylene
- dehydro
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 abstract 2
- 201000006409 renal osteodystrophy Diseases 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010013786 Dry skin Diseases 0.000 abstract 1
- 208000000038 Hypoparathyroidism Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 abstract 1
- 230000000125 calcaemic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000037336 dry skin Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000001616 monocyte Anatomy 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000005368 osteomalacia Diseases 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 210000002374 sebum Anatomy 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 239000011647 vitamin D3 Substances 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
- 229940021056 vitamin d3 Drugs 0.000 abstract 1
- 230000037303 wrinkles Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63000704P | 2004-11-22 | 2004-11-22 | |
| PCT/US2005/041820 WO2006057901A2 (en) | 2004-11-22 | 2005-11-18 | 2-METHYLENE-19-NOR-1α-HYDROXY-17-ENE-HOMOPREGNACALCIFEROL AND ITS USES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE469883T1 true ATE469883T1 (de) | 2010-06-15 |
Family
ID=36216285
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05851805T ATE469883T1 (de) | 2004-11-22 | 2005-11-18 | 2-methylen-19-nor-1alpha-hydroxy-17- enhormopregnacalziferol und anwendungen davon |
| AT05849730T ATE469127T1 (de) | 2004-11-22 | 2005-11-18 | 17,20(z)-dehydro-vitamin-d-analoge und deren verwendungen |
| AT05851757T ATE465144T1 (de) | 2004-11-22 | 2005-11-18 | 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05849730T ATE469127T1 (de) | 2004-11-22 | 2005-11-18 | 17,20(z)-dehydro-vitamin-d-analoge und deren verwendungen |
| AT05851757T ATE465144T1 (de) | 2004-11-22 | 2005-11-18 | 17,20(e)-dehydro-vitamin-d-analoga und deren verwendungen |
Country Status (11)
| Country | Link |
|---|---|
| US (6) | US7241752B2 (enExample) |
| EP (3) | EP1828114B1 (enExample) |
| JP (3) | JP5043673B2 (enExample) |
| AT (3) | ATE469883T1 (enExample) |
| AU (3) | AU2005309806B2 (enExample) |
| CA (3) | CA2588401C (enExample) |
| DE (3) | DE602005020842D1 (enExample) |
| ES (3) | ES2347058T3 (enExample) |
| MX (3) | MX2007006261A (enExample) |
| NZ (3) | NZ555282A (enExample) |
| WO (3) | WO2006057900A2 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030188756A1 (en) * | 2002-08-19 | 2003-10-09 | Cantorna Margherita T | Treatment of inflammatory bowel disease with vitamin d compounds |
| US8404667B2 (en) * | 2006-12-29 | 2013-03-26 | Wisconsin Alumni Research Foundation | Compounds, compositions, kits and methods of use to orally and topically treat acne and other skin conditions by 19-Nor vitamin D analog |
| DE602005021245D1 (de) * | 2004-11-22 | 2010-06-24 | Wisconsin Alumni Res Found | 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen |
| AU2005309806B2 (en) * | 2004-11-22 | 2012-03-08 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses |
| TW200838544A (en) * | 2007-01-25 | 2008-10-01 | Bioxell Spa | Synthesis of 1 α-fluoro-25-hydroxy-16-23E-diene-26, 27-bishomo-20-epi-cholecalciferol |
| US7888339B2 (en) * | 2008-07-10 | 2011-02-15 | Wisconsin Alumni Research Foundation | 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs |
| US7893043B2 (en) * | 2008-07-10 | 2011-02-22 | Wisconsin Alumni Research Foundation | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs |
| EP2387407A4 (en) * | 2009-01-16 | 2012-06-27 | Pharmaceutical Compounding Nz Ltd | MEDICAMENT FOR THE TREATMENT OF PAIN AND INFLAMMATION |
| US20120237472A1 (en) * | 2009-07-24 | 2012-09-20 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
| EP2525799B1 (en) * | 2009-10-02 | 2014-09-03 | Wisconsin Alumni Research Foundation | (20s,22e)-2-methylene-19-nor-22-ene-1alpha,25-dihydroxyvitamin d3 analogs |
| US8664206B2 (en) | 2010-03-23 | 2014-03-04 | Wisconsin Alumni Research Foundation | Diastereomers of 2-methylene-19-nor-22-methyl-1α,25-dihydroxyvitamin D3 |
| US8604009B2 (en) * | 2010-03-23 | 2013-12-10 | Wisconsin Alumni Research Foundation | (20S)-2-methylene-19-nor-22-dimethyl-1α,25-dihydroxyvitamin D3 and (20R)-2-methylene-19-nor-22-dimethyl-1α,25-hydroxyvitamin D3 |
| US20110237557A1 (en) * | 2010-03-23 | 2011-09-29 | Deluca Hector F | Diastereomers of 2-methylene-19-nor-22-methyl-1alpha,25-dihydroxyvitamin d3 |
| WO2013059060A1 (en) * | 2011-10-21 | 2013-04-25 | Wisconson Alumni Research Foundation | 2-methylene-vitamin d analogs and their uses |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
| US5145846A (en) * | 1988-01-20 | 1992-09-08 | Hoffmann-La Roche Inc. | Vitamin D3 analogs |
| GB9004544D0 (en) * | 1990-03-01 | 1990-04-25 | Leo Pharm Prod Ltd | Novel treatment ii |
| US5362719A (en) * | 1990-03-01 | 1994-11-08 | Leo Pharmaceutical Products, Ltd. A/S Lovens Kemiske Fabrik Produktionsaktieselskab) | Use of vitamin-D analogues in the treatment of acne |
| ES2070307T3 (es) * | 1990-07-04 | 1995-06-01 | Marcin Krotkiewski | Una preparacion para el tratamiento de la hipertension. |
| US5086191A (en) * | 1991-05-28 | 1992-02-04 | Wisconsin Alumni Research Foundation | Intermediates for the synthesis of 19-nor vitamin D compounds |
| GB9214202D0 (en) * | 1992-07-03 | 1992-08-12 | Leo Pharm Prod Ltd | Chemical compounds |
| JP2898882B2 (ja) * | 1993-04-05 | 1999-06-02 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ２−位に置換基を有する１９−ノル−ビタミンｄ３ 化合物 |
| US5552392A (en) * | 1993-11-03 | 1996-09-03 | Wisconsin Alumni Research Foundation | Method of treating hypoparathyroidism with (20S) vitamin D compounds |
| DK0717034T3 (da) * | 1994-12-14 | 1999-10-18 | Duphar Int Res | Vitamin D-forbindelser og fremgangsmåde til fremstilling af disse forbindelser |
| GB9625271D0 (en) * | 1996-12-04 | 1997-01-22 | Leo Pharm Prod Ltd | Chemical compounds |
| AU750451B2 (en) * | 1997-02-13 | 2002-07-18 | Bone Care International, Inc. | Targeted therapeutic delivery of vitamin D compounds |
| US6316642B1 (en) * | 1997-03-17 | 2001-11-13 | Wisconsin Alumni Research Foundation | 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds |
| US5843928A (en) * | 1997-03-17 | 1998-12-01 | Wisconsin Alumni Research Foundation | 2-alkylidene-19-nor-vitamin D compounds |
| US6306844B1 (en) * | 1997-03-17 | 2001-10-23 | Wisconsin Alumni Research Foundation | Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength |
| US5945410A (en) * | 1997-03-17 | 1999-08-31 | Wisconsin Alumni Research Foundation | 2-alkyl-19-nor-vitamin D compounds |
| US6392071B1 (en) * | 1997-03-17 | 2002-05-21 | Wisconsin Alumni: Research Foundation | 26,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds |
| US5936105A (en) * | 1997-06-13 | 1999-08-10 | Tetrionics, Inc. | 14-EPI-19-nor-vitamin D compounds and methods |
| CN1090180C (zh) * | 1997-06-25 | 2002-09-04 | 帝人株式会社 | 维生素d3衍生物及其用于炎性呼吸道疾病的治疗剂 |
| GB9721156D0 (en) * | 1997-10-06 | 1997-12-03 | Leo Pharm Prod Ltd | Novel vitamin d analogues |
| EP2340840B1 (en) * | 1998-03-27 | 2012-08-29 | Oregon Health Sciences University | Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases |
| US6806262B2 (en) * | 2000-05-31 | 2004-10-19 | Wisconsin Alumni Research Foundation | 2-ethyl and 2-ethylidene-19-nor-vitamin D compounds |
| IL153378A0 (en) * | 2000-07-18 | 2003-07-06 | Bone Care Internat Inc | STABILIZED 1alpha-HYDROXY VITAMIN D |
| AU7544501A (en) * | 2000-09-08 | 2002-03-22 | Wisconsin Alumni Res Found | 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its therapeutic applications |
| US20040214803A1 (en) | 2001-05-22 | 2004-10-28 | Luciano Adorini | Use of vitamin d3 analogue for the treatment of autoimmune diabetes |
| US6627622B2 (en) | 2002-02-18 | 2003-09-30 | Wisconsin Alumni Research Foundation | (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses |
| US6566352B1 (en) * | 2002-02-18 | 2003-05-20 | Wisconsin Alumni Research Foudation | 1 α-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| ATE346839T1 (de) * | 2002-03-29 | 2006-12-15 | Wisconsin Alumni Res Found | Ein verfahren zur herstellung von 1-alpha-hydroxy-2-methylen-19-nor-homopregnacal iferol |
| US6846811B2 (en) * | 2002-04-22 | 2005-01-25 | Wisconsin Alumni Research Foundation | (20S) 1α-hydroxy-2α-methyl and 2β-methyl-19-nor-vitamin D3 and their uses |
| GB0305332D0 (en) | 2003-03-10 | 2003-04-09 | Leuven K U Res & Dev | Biological evaluation of novel vitamin D analogues |
| US20050009792A1 (en) | 2003-07-08 | 2005-01-13 | Deluca Hector F. | (20S)-1alpha-hydroxy-2-methylene-19-nor-vitamin D3 and its uses |
| WO2005051396A2 (en) * | 2003-11-25 | 2005-06-09 | Deltanoid Pharmaceuticals, Inc. | Methods for reducing body fat using vitamin d compounds |
| WO2005051323A2 (en) * | 2003-11-25 | 2005-06-09 | Wisconsin Alumni Research Foundation | Vitamin d analogs for obesity prevention and treatment |
| WO2006057884A2 (en) | 2004-11-22 | 2006-06-01 | Wisconsin Alumni Research Foundation | 2α-METHYL AND 2ß-METHYL ANALOGS OF 19,26,27-TRINOR-(20S)-1α-HYDROXYVITAMIN D3 AND THEIR USES |
| AU2005309806B2 (en) * | 2004-11-22 | 2012-03-08 | Wisconsin Alumni Research Foundation | 2-methylene-19-nor-1alpha-hydroxy-17-ene-homopregnacalciferol and its uses |
| NZ570814A (en) | 2006-04-06 | 2011-11-25 | Wisconsin Alumni Res Found | 2-methylene-1alpha-hydroxy-19,21-dinorvitamin D3 analogs and uses thereof |
| PT2148684E (pt) * | 2007-04-25 | 2013-04-19 | Cytochroma Inc | Método de tratamento para a insuficiência e deficiência de vitamina d |
-
2005
- 2005-11-18 AU AU2005309806A patent/AU2005309806B2/en not_active Expired - Fee Related
- 2005-11-18 US US11/283,291 patent/US7241752B2/en not_active Expired - Lifetime
- 2005-11-18 US US11/283,090 patent/US7241748B2/en not_active Expired - Lifetime
- 2005-11-18 CA CA2588401A patent/CA2588401C/en not_active Expired - Fee Related
- 2005-11-18 DE DE602005020842T patent/DE602005020842D1/de not_active Expired - Lifetime
- 2005-11-18 DE DE602005021538T patent/DE602005021538D1/de not_active Expired - Lifetime
- 2005-11-18 MX MX2007006261A patent/MX2007006261A/es active IP Right Grant
- 2005-11-18 CA CA2588410A patent/CA2588410C/en not_active Expired - Fee Related
- 2005-11-18 ES ES05851805T patent/ES2347058T3/es not_active Expired - Lifetime
- 2005-11-18 ES ES05851757T patent/ES2344989T3/es not_active Expired - Lifetime
- 2005-11-18 CA CA2588396A patent/CA2588396C/en not_active Expired - Fee Related
- 2005-11-18 WO PCT/US2005/041819 patent/WO2006057900A2/en not_active Ceased
- 2005-11-18 AT AT05851805T patent/ATE469883T1/de not_active IP Right Cessation
- 2005-11-18 NZ NZ555282A patent/NZ555282A/en not_active IP Right Cessation
- 2005-11-18 JP JP2007543228A patent/JP5043673B2/ja not_active Expired - Fee Related
- 2005-11-18 NZ NZ555278A patent/NZ555278A/en not_active IP Right Cessation
- 2005-11-18 AU AU2005309790A patent/AU2005309790B2/en not_active Ceased
- 2005-11-18 MX MX2007006546A patent/MX2007006546A/es active IP Right Grant
- 2005-11-18 WO PCT/US2005/041670 patent/WO2006057885A2/en not_active Ceased
- 2005-11-18 JP JP2007543269A patent/JP2008520705A/ja active Pending
- 2005-11-18 DE DE602005021702T patent/DE602005021702D1/de not_active Expired - Lifetime
- 2005-11-18 EP EP05851757A patent/EP1828114B1/en not_active Expired - Lifetime
- 2005-11-18 AU AU2005309805A patent/AU2005309805B2/en not_active Ceased
- 2005-11-18 ES ES05849730T patent/ES2346774T3/es not_active Expired - Lifetime
- 2005-11-18 WO PCT/US2005/041820 patent/WO2006057901A2/en not_active Ceased
- 2005-11-18 US US11/283,125 patent/US7241750B2/en not_active Expired - Lifetime
- 2005-11-18 AT AT05849730T patent/ATE469127T1/de not_active IP Right Cessation
- 2005-11-18 AT AT05851757T patent/ATE465144T1/de not_active IP Right Cessation
- 2005-11-18 JP JP2007543268A patent/JP5161582B2/ja not_active Expired - Fee Related
- 2005-11-18 MX MX2007006262A patent/MX2007006262A/es active IP Right Grant
- 2005-11-18 EP EP05851805A patent/EP1846370B1/en not_active Expired - Lifetime
- 2005-11-18 NZ NZ555277A patent/NZ555277A/en not_active IP Right Cessation
- 2005-11-18 EP EP05849730A patent/EP1817279B1/en not_active Expired - Lifetime
-
2007
- 2007-07-09 US US11/775,117 patent/US7704982B2/en not_active Expired - Fee Related
- 2007-07-09 US US11/775,108 patent/US7741313B2/en not_active Expired - Fee Related
- 2007-07-09 US US11/775,061 patent/US8232263B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60215225D1 (de) | Alpha-hydroxy-2-methylen-10-nor-pregnacalciferol und seine anwendungen | |
| MX2007006263A (es) | Analogos 2a-metil y 2??-metil de 19,26,27-trinor-(20s)-1a- hidroxivitamina d3 y sus usos. | |
| PT1315504E (pt) | 1-alfa-hidroxi-2-metileno-19-nor-homopregnacalciferol e suas aplicacoes terapeuticas | |
| ATE415164T1 (de) | (20s)-1alpha-hydroxy-2alpha-methyl und 2beta- methyl-19-nor vitamin d3 und ihre verwendung | |
| ATE552239T1 (de) | 2-methylen-20-methyl-19,24,25,26,27-pentanor- vitamin-d-analoga | |
| ATE469883T1 (de) | 2-methylen-19-nor-1alpha-hydroxy-17- enhormopregnacalziferol und anwendungen davon | |
| WO2006057899A3 (en) | 2alpha-methyl-19-nor-(20s)-1alpha-hydroxy-bishomopregnacalciferol and its uses | |
| MX2009003241A (es) | Analogos de 2-metilen-(20r,25s)-19,27-dinor-(22e)-vitamina d. | |
| DE602005021245D1 (de) | 2-methylen-19,26,27-trinor-(20s)-1-alpha-hydroxyvitamin d3 and dessen verwendungen | |
| MX2010007264A (es) | Análogos de vitamina d 2-metilen-(20s, 25r)-19, 26-dinor. | |
| DK1453798T3 (da) | (20S)-1alfa-hydroxy-2-methylen-19-nor-bishomopregnacalciferol og anvendelser deraf | |
| ATE552238T1 (de) | 2-methylen-(20s,25s)-19,27-dinor-(22e)-vitamin- - analoga | |
| WO2010006125A3 (en) | 2-methylene-19,26-dinor-(20r,22e,25r)-vitamin d analogs | |
| WO2010006169A3 (en) | 2-methylene-19, 26-dinor-(20s, 22e, 25r)-vitamin d analogs | |
| ATE472528T1 (de) | 2-methylen-18,19-dinor-1alfa-hydroxy- homopregnacalciferol und dessen verwendungen | |
| WO2010006172A3 (en) | 2-methylene-20(21)-dehydro-19-nor-vitamin d analogs | |
| WO2010006135A3 (en) | 2-methylene-(17z)-17(20)-dehydro-19,21-dinor-vitamin d analogs | |
| WO2010006162A3 (en) | 2-methylene-(20e)-20(22)-dehydro-19-nor-vitamin d analogs | |
| WO2006057902A3 (en) | 2alpha-methyl-19-nor-1alpha-hydroxy-homopregnacalciferol and its uses | |
| WO2009086439A3 (en) | 2-methylene-(20s,25s)-19,26-dinor-vitamin d analogs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |